Shots:

• The US FDA has granted Emergency Use Authorization (EUA) for its rapid point-of-care BD Veritor SARS-CoV-2 Assay which allows the result in 15 mins evaluated in 20 sites across the US with 84% sensitivity and 100% specificity. Additionally- BD plans for increasing capacity to produce 2M tests per week by the end of September with an expected production of up to 10M tests from July through September
• The BD Veritor System is a one-button functionality with workflow flexibility offering real-time data with BD Synapsys informatics solution used in 25000+ hospitals- clinician offices- care centers and pharmacies in all 50 the US states  
• BD Veritor SARS-CoV-2 Assay is the third test added to the portfolio of two with EUAs and two with the CE mark in use with the BD MAX Molecular System. Additionally- the company plans for 510(k) clearance for the assay and interested US customers in BD diagnostic solutions contact IDS.COVIDtests@bd.com

Click here to read full press release/ article | Ref: Becton Dickinson | Image: Twitter